A Case Report: Rapid Micro‐Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended‐Release in an Adolescent With Severe Opioid Use Disorder-Reference-Cited by-同舟云学术

A Case Report: Rapid Micro‐Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended‐Release in an Adolescent With Severe Opioid Use Disorder

Published:2020-04-29 Issue:6 Volume:29 Page:531-535
ISSN:1055-0496
Container-title:The American Journal on Addictions
language:en
Short-container-title:Am J Addict

Author:

Azar Pouya¹,Wong James S.H.²^ORCID,Jassemi Sara³,Moore Eva³,Vo Dzung X.³,Nikoo Mohammadali²^ORCID,Young Samantha⁴⁵

Affiliation:

1. Vancouver General Hospital University of British Columbia Vancouver British Columbia Canada

2. Addictions and Concurrent Disorders Research Group, Department of Psychiatry Institute of Mental Health University of British Columbia Vancouver British Columbia Canada

3. Department of Pediatrics, Division of Adolescent Health and Medicine B.C. Children’s Hospital University of British Columbia Vancouver British Columbia Canada

4. British Columbia Centre on Substance Use, British Columbia Centre for Excellence, St. Paul’s Hospital Vancouver British Columbia Canada

5. Department of Medicine, Interdepartmental Division of Addiction Medicine St. Paul’s Hospital Vancouver British Columbia Canada

Funder

Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarships

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Psychology,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajad.13050

Reference20 articles.

1. Assessment of Changes in the Geographical Distribution of Opioid-Related Mortality Across the United States by Opioid Type, 1999-2016

2. At-a-glance - Impact of drug overdose-related deaths on life expectancy at birth in British Columbia

3. Indivior PLC. SUBLOCADE.https://www.sublocade.com. Accessed 2 December 2019.

4. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

5. Government of Canada. Regulatory Decision Summary—Sublocade—Health Canada. Government of Canada; 2019.https://hpr‐rps.hres.ca/reg‐content/regulatory‐decision‐summary‐detail.php?linkID=RDS00462. Accessed 2 December 2019.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergency department management of opioid use disorder in pediatric patients;Journal of the American College of Emergency Physicians Open;2024-08-25

2. Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended – Release Subcutaneous Injection: A Case Report;Journal of Adolescent Health;2024-07

3. Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder;Addiction Science & Clinical Practice;2024-06-18

4. Quantitative and qualitative outcomes associated with inpatient addiction consultation: a scoping review;The American Journal of Drug and Alcohol Abuse;2024-06-06

5. A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder;Drugs in R&D;2023-11-08